Other
Blog in Blog: There are no posts that match the selection criteria.
- Amag Pharma falls after ending sale talks
- OncoMed seeks $115 million IPO
- BMS and Tsinghua University in structural biology research pact
- Menarini licenses rights to Priligy
- The trouble with tech M&A
- Top twenty partnering deals of 2011 have a combined value of over $21 billion
- The Hep C club: the new dealmakers hot spot
- Vical and Teva Pharmaceutical establish sales and marketing agreement for Allovectin-7(r) in Israel
- Biopharma partnering: Perspectives from BCG’s latest biotech and pharma partnering study
- Biotech investing at a crossroads?
- Steve Poile: HI Beverly Sure, your email address is added an...
- Beverly Cormier: This is a great report. I would to receive it via...
- Rob Grundy: Hi Bruce, Great article. 'Let me frame up tw...
- Joe Patti: Jan. 24, 2012-BioLineRx signed an “exclusive licen...
- Steve Poile: Hi Kevin Thanks for this. I believe it is alrea...
Home | Reports | Services | Insight | News | Events | Scorecard | About us | Terms & conditions | Subscribe | Contact us
© 2012 Wildwood Ventures Ltd. 